These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 22268920

  • 21. The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP.
    Nielsen SE, Rossing K, Hess G, Zdunek D, Jensen BR, Parving HH, Rossing P.
    Scand J Clin Lab Invest; 2012 Apr; 72(2):137-42. PubMed ID: 22268365
    [Abstract] [Full Text] [Related]

  • 22. Blood pressure reduction as a preventive treatment of diabetic nephropathy.
    Ribstein J, Mimran A.
    Clin Invest Med; 1991 Dec; 14(6):661-70. PubMed ID: 1794216
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
    Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH.
    Kidney Int; 2006 Aug; 70(3):536-42. PubMed ID: 16775595
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [Abstract] [Full Text] [Related]

  • 28. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG, Davis WA, Kamber N, Sivakumar S, Beilby J, Davis TM.
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
    Saklayen MG, Gyebi LK, Tasosa J, Yap J.
    J Investig Med; 2008 Apr; 56(4):714-9. PubMed ID: 18382267
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.
    Nephrol Dial Transplant; 2002 Jun; 17(6):1019-24. PubMed ID: 12032191
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Jensen BR, Parving HH.
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.